PPARG and cancer: A novel high-affinity PPARγ agonist, and thiazolidinedione derivative, RS5444, demonstrated additive antiproliferative activity on DRO90-1 and ARO81 anaplastic thyroid carcinoma cells, a particularly aggressive and dedifferentiated cancer [67].